Combination Strategies of Checkpoint Immunotherapy in Metastatic Breast Cancer.

Onco Targets Ther · 2020 · PMC7133118 · PMID 32308409

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The median OS data of ITT patients did not reach statistical significance, but a 7.0-month improvement in median OS was observed in PD-L1-positive patients with combination treatment compared with atezolizumab monotherapy.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.